Who is sponsoring NCT04476043?

NCT04476043 is sponsored by Incyte Corporation.

What condition does NCT04476043 study?

NCT04476043 studies Hidradenitis Suppurativa, Acne Inversa.

What drugs are being tested in NCT04476043?

Interventions: INCB054707, Placebo.

What is the status of NCT04476043?

NCT04476043 is currently COMPLETED.

Last reviewed 2025-08-12 · How we verify

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT04476043 PHASE2 COMPLETED Results posted

To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period. All eligible participants will be invited to continue treatment for an additional 48-week Long-term extension period (also open label).

Details

Lead sponsor	Incyte Corporation
Phase	PHASE2
Status	COMPLETED
Enrolment	209
Start date	Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Aug 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Hidradenitis Suppurativa
Acne Inversa

Interventions

INCB054707
Placebo

Countries

France, Germany, Poland, Canada, United States, Spain